ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma20/10/2025PR Newswire
Day 2 of 2025 Sustainable Global Leaders Conference: Nobel Laureate Shares AI Insights, Major ESG Achievements Announced20/10/2025PR Newswire
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 202520/10/2025PR Newswire
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer20/10/2025PR Newswire
Chengdu CATANIA’s Tower 2 Debuts Globally: A 222-Meter-High Sky Residence Redefining Global Luxury Living.20/10/2025PR Newswire
MILESEEY GenePro G1 Named to TIME’s “The Best Inventions of 2025: Special Mentions”20/10/2025PR Newswire
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO20/10/2025PR Newswire
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions20/10/2025PR Newswire
Accord Plasma B.V. ขยายขีดความสามารถด้านการบำบัดด้วยพลาสมาระดับโลก ด้วยการเข้าซื้อกิจการ Prothya Biosolutions20/10/2025PR Newswire
